In the News

submenu
Rally orgs

The Minnesota Rally For Research is happening on Saturday, August 5 from 1:00 to 2:30 pm at the Minnesota State Capitol in Saint Paul. It’s one of many that will be taking place across the country in August.

Illini 4000 Riders

Earlier this summer, cyclists with the Illini 4000 made a detour to the St. Paul campus at the University of Minnesota to meet with researchers from the Department of Biochemistry, Molecular Biology, and Biophysics. The Illini 4000 is a non-profit organization dedicated to documenting the American cancer experience through The Portraits Project, raising funds for cancer research and patient support services, as well as spreading awareness for the fight against cancer through annual cross-country bike rides.

The decrease in cancer death rates in the United States has been uplifting news for the nation and a great source of hope for the cancer research community. A point of frustration, however, has been the continued ethnic/racial and socioeconomic disparities in cancer outcomes.

Jakub Tolar, M.D., Ph.D., Transplant Biology and Therapy Program, recently gave a TedXFargo talk about his research and groundbreaking treatment of a serious skin disorder called Epidermolysis Bullosa. 

Todd M. Tuttle, M.D., Screening, Prevention, Etiology and Cancer Survivorship Program, was quoted in a KTBS News story about the tripling of double mastectomies for breast cancer tripled the past 10 years.

Daniel A. Vallera, Ph.D., Tumor Microenvironment Program, and Veronika Bachanova, M.D., Ph.D., Transplant Biology and Therapy Program, were featured in a KARE11 “Tackle Cancer” story about how donations and research helped University of Minnesota physics professor, Cynthia Cattell, fight cancer.

Aasma Shaukat, MD,Screening, Prevention, Etiology and Cancer Outcomes (SPECS) Program, was quoted in a Medicine Net story about a new at-home colon cancer test.

Jeffrey Miller, MD, Transplant Biology and Therapy Program, and Daniel Vallera, PhD, Tumor Microenvironment Program, were quoted in reports on Oxis Biotech signing an exclusive license agreement with University of Minnesota to develop and commercialize of its cancer therapies using Trispecific Killer Engager (TriKE) technology.

Pages